Earnings Feed
Start Free
MERIT MEDICAL SYSTEMS INC·4

Mar 2, 2:04 PM ET

Lloyd Brian G. 4

4 · MERIT MEDICAL SYSTEMS INC · Filed Mar 2, 2026

Research Summary

AI-generated summary of this filing

Updated

Merit Medical (MMSI) CLO Brian G. Lloyd Receives RSUs, Surrenders Shares

What Happened

  • Brian G. Lloyd, Chief Legal Officer and Secretary of Merit Medical Systems, received equity awards (grants) totaling 33,665 shares on 2026-02-26 (three separate awards of 10,254; 6,409; and 17,002 shares; acquisition price $0.00). On the same date he surrendered 5,778 shares to the company to satisfy payroll and income tax withholding obligations at $78.02 per share, a withholding value of $450,800. This was an award/grant (A) and a tax-withholding disposition (F), not an open-market sale.

Key Details

  • Transaction date: 2026-02-26; Form 4 filed 2026-03-02 (filed within required business-day window).
  • Awards: 10,254; 6,409; and 17,002 RSUs/PSUs granted (total 33,665) at $0.00 (code A).
  • Tax withholding: 5,778 shares surrendered at $78.02/share, total $450,800 (code F). No open-market sale occurred.
  • Vesting/award notes:
    • Some grants are RSUs that vest over multi-year schedules (F1: 3 equal annual installments; F2: 2 equal installments on years 2 and 3).
    • One award reflects performance stock units determined vested from a 02/28/2023 PSU grant (F3).
    • The surrendered shares were used for payroll and income taxes (F4).
  • Shares owned after transaction: not specified in the Form 4.

Context

  • These transactions are routine compensation-related actions: the company granted RSUs/PSUs (future contingent rights to shares) and the insider surrendered shares to cover tax withholding. This is different from a market sale — no shares were sold on the open market. Awards signal compensation recognition but are not the same as a cash purchase by the insider.

Insider Transaction Report

Form 4
Period: 2026-02-26
MERIT MEDICAL SYSTEMS INCMMSI
Lloyd Brian G.
CHIEF LEGAL OFFICER, SECRETARY
Transactions
  • Award

    Common Stock, No Par Value

    [F1]
    2026-02-26+10,254→ 44,499 total
  • Award

    Common Stock, No Par Value

    [F2]
    2026-02-26+6,409→ 50,908 total
  • Award

    Common Stock, No Par Value

    [F3]
    2026-02-26+17,002→ 67,910 total
  • Tax Payment

    Common Stock, No Par Value

    [F4]
    2026-02-26$78.02/sh−5,778$450,800→ 62,132 total
Holdings

  • Non-qualified stock options (right to buy)

    [F5]
    Exercise: $37.71From: 2021-02-26Exp: 2027-02-26→ Common Stock (16,722 underlying)
    16,722

  • Non-qualified stock options (right to buy)

    [F6]
    Exercise: $56.25From: 2022-03-19Exp: 2028-03-19→ Common Stock (9,681 underlying)
    9,681

  • Non-qualified stock options (right to buy)

    [F7]
    Exercise: $65.03From: 2023-02-28Exp: 2029-02-28→ Common Stock (8,094 underlying)
    8,094

  • Non-qualified stock options (right to buy)

    [F8]
    Exercise: $70.58From: 2024-02-28Exp: 2030-02-28→ Common Stock (13,576 underlying)
    13,576
Footnotes (8)
  • [F1]Represents a grant of restricted stock units ("RSUs"). The RSUs vest in three equal annual installments on each of the first three anniversaries of the grant date, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the contingent right to receive one share of Common Stock upon vesting.
  • [F2]Represents a grant of RSUs. The RSUs vest in two equal installments on each of the second and the third anniversaries of the grant date, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the contingent right to receive one share of Common Stock upon vesting.
  • [F3]These shares were acquired upon a determination of the Company's Compensation and Talent Development Committee that certain conditions had been met for the issuance of such shares pursuant to performance stock units that were granted on 02/28/2023.
  • [F4]The Reporting Person surrendered 5,778 shares of common stock to the Issuer for payroll and income taxes. No shares were sold in the open market.
  • [F5]Become exercisable in equal annual installments of 25% commencing on 02/26/2021.
  • [F6]Become exercisable in equal annual installments of 25% commencing on 03/19/2022.
  • [F7]Becomes exercisable in equal annual installments of 25% commencing 02/28/2023.
  • [F8]Become exercisable in equal annual installments of 25% commencing on 02/28/2024.
Signature
/s/ Brian G.Lloyd|2026-03-02

Documents

2 files